Extended Review Timeline for Certain Applications under Proposed PDUFA V

May 21, 2012

The Prescription Drug User Fee Act (PDUFA) is due to be reauthorized by the end of September this year. Along with the usual increases in fees, the latest version of the act (PDUFA V) includes some new initiatives. One of these is a program for enhanced review transparency and communication which will apply to all New Molecular Entity (NME) New Drug Applications (NDAs) and original Biologics License Applications (BLAs). This includes applications that are submitted following a Refuse-To-File action.

Included in the program are specific meetings between the Agency and the Sponsor (e.g. pre-submission meeting, late-cycle meeting) as well as other communications. One very important change to this program affects the overall review timeline for a submission. For NME NDA and original BLA submissions that are filed by FDA under the program, the PDUFA review clock will begin at the conclusion of the 60 calendar day filing review period that begins on the date of FDA receipt of the original submission. What this means is that sponsors who submit NME NDAs and original BLAs on or after October 1, 2012 will have a two month longer review period than those submitted prior to that date. For sponsors looking at a filing date near the September 30th deadline, this new program provides additional incentive to file before the new timeline takes effect.

If you have any questions or thoughts on this blog post or others, please contact us.




Agency Alerts General Regulatory

May 21, 2012

FDA Announces Rate for Rare Pediatric Disease Priority Review Vouchers to Increase in 2016

FDA has released the fiscal year 2016 fee rate for using a rare pediatric disease priority review voucher. The new rate for 2016 will be $2,727,000, up from 2015’s rate of $2,562,000, and will take...

Read More
Agency Alerts General Regulatory

May 21, 2012

FDA To Increase Tropical Disease Priority Review User Fee Rate In 2016

Starting October 1, 2015, the FDA tropical disease priority review user fee rate is set to increase to $2,727,000, up nearly $200,000 from 2015’s rate of $2,562,000. Under the Prescription Drug User...

Read More
Medical Device Agency Alerts

May 21, 2012

Draft Guidance: Requesting Nonbinding Feedback After an FDA Inspection of Your Medical Device Establishment

On Tuesday, February 19th, FDA published a draft guidance for medical device makers which identifies a process for companies to request nonbinding feedback on certain FDA Form 483 deficiencies noted...

Read More